Press release
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis, Size, Share, Growth To 2020 by Grand View Research, Inc.
Corticosteroids are the most frequently administered therapy for idiopathic thrombocytopenic purpura (ITP). The global corticosteroids market for ITP was valued at over USD 125.0 million in 2013. Corticosteroids are considered as the first line of treatment in patients with ITP and therefore, enjoy very high usage rates.
Browse full research report on Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market: http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics
Further key findings from the study suggest:
• TPO-RA is the most lucrative segment of this market and is expected to witness a surge in demand owing to the potential commercialization of Avatrombopag in 2015. Moreover, the ability of this class to cater to splenectomized patients witnessing relapses attributes to such rapid growth.
• North America accounted for over 40% of the global ITP market revenue in 2013, on account of high market penetration rates and favorable regulations. Presence of an extensive number of clinical trial studies related to combination therapy and new product development is also expected to drive regional growth during the forecast period.
• Europe was the second largest regional ITP therapeutics market in 2013 and is expected to maintain its position over the forecast period. High product usage rates and the presence of government initiatives granting special status to orphan drugs are some factors accounting for its large market share.
• Asia Pacific is expected to present high future growth potential over the next six years, owing to the presence of large untapped opportunities in the emerging markets of India and China. Presence of favorable government initiatives and sophisticated healthcare infrastructure in Japan and Australia are also expected to attribute to its market attractiveness.
• Key players of the ITP therapeutics market include GSK, Amgen Inc., Grifols Biologicals Inc., Eisai and F.Hoffman-La Roche.
Read detailed report or request for sample of this research report:
http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics/request
For the purpose of this study, Grand View Research has segmented the global ITP therapeutics market on the basis of product and region:
Global ITP Therapeutics Product Outlook (Revenue, USD Million, 2012 – 2020)
• Corticosteroids
• Intravenous Immunoglobulin (IVIG)
• Anti-D Immunoglobulin
• Thrombopoietin Receptor Agonists (TPO-RA)
• Others
ITP Therapeutics Regional Outlook (Revenue, USD Million, 2012 – 2020)
• North America
• U.S.
• Mexico
• Europe
• Germany
• UK
• Asia Pacific
• India
• Japan
• China
• RoW
• Brazil
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Web: grandviewresearch.com
Read our blogs - dniamericas.org, divog.org, legalworkshop.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis, Size, Share, Growth To 2020 by Grand View Research, Inc. here
News-ID: 324922 • Views: …
More Releases from Grand View Research, Inc.
Generative AI Market Size, Share, And Industry Outlook Report, 2030
Generative AI Market Growth & Trends
The global generative AI market size is anticipated to reach USD 109.37 billion by 2030, according to a new report by Grand View Research, Inc., registering a CAGR of 37.6% from 2025 to 2030. Growing demand to modernize workflow across industries is expected to drive the demand for generative AI applications among industries. Other factors that propel the market growth include the evolution of AI…
Maternal Mental Health Market To Reach $45.72 Billion By 2030 | Therapy Mama, Ca …
The global maternal mental health market size is expected to reach USD 45.72 billion by 2030, growing at a CAGR of 28.43%, according to a new report by Grand View Research, Inc. Maternal mental health issues are a global concern that affects women of various countries and cultures. It refers to the emotional well-being of women during the pregnancy and postpartum period. The market is driven by the increasing incidence…
Downstream Processing Market Size, Share & Trends Analysis Report, 2030
The global downstream processing market size is expected to reach USD 94.79 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.84% from 2023 to 2030. The capacity requirements during the development of biologic drugs have changed over the past few years, wherein the demand for manufacturing high-volume products has shifted to developing small-volume, high-potency…
Electric Mobility Industry: E- Light Commercial Vehicle Thereby Contributing To …
The global electric mobility industry size stood at USD 101.67 billion in 2022 and will exhibit a CAGR of 19.9% from 2023 to 2030, according to the "Electric Mobility Industry Data Book, 2023 - 2030," published by Grand View Research. The growth comes on the back of an exponential rise in smart cities and a gradual uptick in charging infrastructure. Further, the strong outlook of electric mobility will rely on the launch…
More Releases for ITP
Immune Thrombocytopenia ITP Market Booming with New Therapeutic Approaches | Coh …
📊 Immune Thrombocytopenia ITP Market Snapshot 2025-2032
Immune Thrombocytopenia (ITP) Market is expected to reach USD 3.1 Billion by 2032, growing at a CAGR of 4.9% during 2025 to 2032.
Coherent Market Insights unveils its latest data-driven Immune Thrombocytopenia ITP Market Research Report featuring transformative insights into the U.S. Immune Thrombocytopenia ITP Market. Spanning from 2025 to 2032, this report offers granular forecasts, payer-provider models, and supply chain intelligence. As the U.S.…
ITP Therapeutics Market to Reach US$ 1.0 Billion by 2032: Fact.MR
The global Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market has experienced notable growth in recent years, driven by factors such as increased awareness of autoimmune diseases, advancements in targeted therapies, and a rising prevalence of ITP among the geriatric population. According to Fact.MR, the market was valued at approximately US$ 587.0 million in 2021 and is projected to reach US$ 1.0 billion by 2032, reflecting a compound annual growth rate (CAGR)…
Exploring the Idiopathic Thrombocytopenic Purpura (ITP) Treatment Drugs Market
Idiopathic Thrombocytopenic Purpura (ITP), also known as Immune Thrombocytopenic Purpura, is an autoimmune disorder characterized by abnormally low platelet levels, leading to an increased risk of bruising and bleeding. The condition can affect both children and adults, with treatment options tailored to individual cases based on severity and response to therapy. The growing prevalence of ITP and advancements in treatment approaches have fueled the demand for effective therapeutic drugs, making…
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Futur …
The world of the idiopathic thrombocytopenic purpura (itp) therapeutics market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a…
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market - Competitive Land …
Idiopathic Thrombocytopenic Purpura (ITP) is a condition into which blood doesn't clot normally or failure to blood clot. This condition is commonly referred to as immune thrombocytopenia. ITP can lead to irregular bleeding and brushing. Frequent low blood counts especially platelets and thrombocytes often lead to ITP. Various drug class are available to treat this condition but corticosteroids are the first line therapy.
Download Sample Brochure at: https://www.theinsightpartners.com/sample/TIPRE00016880/?utm_source=OpenPR&utm_medium=10766
Market Dynamics:
The…
Idiopathic Thrombocytopenic Purpura Market - Defy the Odds: Transforming Lives t …
Newark, New Castle, USA: The "Idiopathic Thrombocytopenic Purpura Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Idiopathic Thrombocytopenic Purpura Market: https://www.growthplusreports.com/report/idiopathic-thrombocytopenic-purpura-market/8875
This latest report researches the industry structure,…
